US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US20030109503A1
(en)
*
|
1995-06-06 |
2003-06-12 |
Smithkline Beecham P.L.C. |
Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
ATE302597T1
(en)
|
1997-06-06 |
2005-09-15 |
Depomed Inc |
STOMACH-RESIDENT ORAL DOSAGE FORMS OF WATER-SOLUBLE DRUGS WITH CONTROLLED RELEASE
|
AP1224A
(en)
|
1998-03-19 |
2003-11-14 |
Bristol Myers Squibb Co |
Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
|
US6099859A
(en)
|
1998-03-20 |
2000-08-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral tablet having a unitary core
|
US20040081697A1
(en)
*
|
1998-11-12 |
2004-04-29 |
Smithkline Beecham P.L.C. |
Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
|
US20030153607A1
(en)
*
|
1998-11-12 |
2003-08-14 |
Smithkline Beecham P.L.C. |
Novel composition and use
|
US20040102486A1
(en)
*
|
1998-11-12 |
2004-05-27 |
Smithkline Beecham Corporation |
Novel method of treatment
|
US6294199B1
(en)
|
1999-04-13 |
2001-09-25 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection comprising administering amoxycillin
|
US6878386B1
(en)
|
1999-04-13 |
2005-04-12 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
|
US7250176B1
(en)
|
1999-04-13 |
2007-07-31 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection
|
US6586438B2
(en)
*
|
1999-11-03 |
2003-07-01 |
Bristol-Myers Squibb Co. |
Antidiabetic formulation and method
|
WO2001056544A2
(en)
|
2000-02-04 |
2001-08-09 |
Depomed, Inc. |
Shell-and-core dosage form approaching zero-order drug release
|
US6565882B2
(en)
*
|
2000-02-24 |
2003-05-20 |
Advancis Pharmaceutical Corp |
Antibiotic composition with inhibitor
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
AU2578701A
(en)
*
|
2000-02-29 |
2001-09-12 |
Teva Pharma |
Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
|
WO2001072284A1
(en)
*
|
2000-03-28 |
2001-10-04 |
Biochemie Gesellschaft M.B.H. |
Granulated particles with masked taste
|
US6488962B1
(en)
*
|
2000-06-20 |
2002-12-03 |
Depomed, Inc. |
Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
|
US7527807B2
(en)
*
|
2000-06-21 |
2009-05-05 |
Cubist Pharmaceuticals, Inc. |
Compositions and methods for increasing the oral absorption of antimicrobials
|
US7674480B2
(en)
*
|
2000-06-23 |
2010-03-09 |
Teva Pharmaceutical Industries Ltd. |
Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
|
US6476006B2
(en)
|
2000-06-23 |
2002-11-05 |
Teva Pharmaceutical Industries, Ltd. |
Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
|
US6881420B2
(en)
|
2000-06-23 |
2005-04-19 |
Teva Pharmaceutical Industries Ltd. |
Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
|
DE10031043A1
(en)
*
|
2000-06-26 |
2002-02-14 |
Bayer Ag |
Retarded preparations of quinolone antibiotics and process for their preparation
|
CN1466451B
(en)
*
|
2000-09-29 |
2010-05-12 |
索尔瓦药物有限公司 |
Ion-strength independent sustained release pharmacetuical formulation
|
EP1322158B1
(en)
*
|
2000-10-02 |
2012-08-08 |
USV Ltd. |
Sustained release pharmaceutical compositions containing metformin and method of their production
|
US6756057B2
(en)
|
2000-10-12 |
2004-06-29 |
Beecham Pharmaceuticals (Pte) Limited |
Amoxicillin and potassium clavulanate dosage form
|
EP1330236A2
(en)
|
2000-10-12 |
2003-07-30 |
Beecham Pharmaceuticals (Pte) Limited |
Formulation containing amoxicillin
|
US20020068078A1
(en)
*
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
US6541014B2
(en)
*
|
2000-10-13 |
2003-04-01 |
Advancis Pharmaceutical Corp. |
Antiviral product, use and formulation thereof
|
FR2816840B1
(en)
|
2000-11-17 |
2004-04-09 |
Flamel Tech Sa |
MEDICINE BASED ON SUSTAINED RELEASE ANTI-HYPERCLYCEMIA MICROCAPSULES AND METHOD FOR PREPARING THE SAME
|
US20020197314A1
(en)
*
|
2001-02-23 |
2002-12-26 |
Rudnic Edward M. |
Anti-fungal composition
|
PT1390063E
(en)
*
|
2001-05-03 |
2005-03-31 |
Hoffmann La Roche |
NELFINAVIR AMORFO MESYLATE PHARMACEUTICAL DOSE FORM
|
JP2004532259A
(en)
*
|
2001-05-29 |
2004-10-21 |
デポメッド ディベロップメント リミティド |
Treatment of gastroesophageal reflux disease and recovery of gastric acid secretion at night
|
US6524618B1
(en)
*
|
2001-06-12 |
2003-02-25 |
Vijai Kumar |
Directly compressible extended-release matrix formulation for metformin hydrochloride
|
WO2003004009A1
(en)
*
|
2001-07-02 |
2003-01-16 |
Geneva Pharmaceuticals, Inc. |
Pharmaceutical composition
|
US7776345B2
(en)
*
|
2001-07-04 |
2010-08-17 |
Sun Pharma Advanced Research Company Ltd |
Gastric retention controlled drug delivery system
|
CA2452871C
(en)
*
|
2001-07-06 |
2011-10-04 |
Endo Pharmaceuticals, Inc. |
Oxymorphone controlled release formulations
|
US8329216B2
(en)
*
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
BR0210855A
(en)
*
|
2001-07-06 |
2006-10-24 |
Penwest Pharmaceuticals Compan |
Method of Manufacturing Extended Release Formulations
|
ITMI20011457A1
(en)
*
|
2001-07-09 |
2003-01-09 |
Valpharma Sa |
MODIFIED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING BUPROPIONEHC1 AS ACTIVE SUBSTANCE
|
US20040219186A1
(en)
*
|
2001-08-16 |
2004-11-04 |
Ayres James W. |
Expandable gastric retention device
|
AU2002337686B2
(en)
*
|
2001-09-26 |
2008-05-15 |
Penwest Pharmaceuticals Company |
Opioid formulations having reduced potential for abuse
|
PE20030527A1
(en)
|
2001-10-24 |
2003-07-26 |
Gruenenthal Chemie |
DELAYED-RELEASE PHARMACEUTICAL FORMULATION CONTAINING 3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) PHENOL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND ORAL TABLETS CONTAINING IT
|
US7612112B2
(en)
|
2001-10-25 |
2009-11-03 |
Depomed, Inc. |
Methods of treatment using a gastric retained gabapentin dosage
|
TWI312285B
(en)
*
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
US6723340B2
(en)
*
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
US20060159743A1
(en)
*
|
2001-10-25 |
2006-07-20 |
Depomed, Inc. |
Methods of treating non-nociceptive pain states with gastric retentive gabapentin
|
US20030104052A1
(en)
*
|
2001-10-25 |
2003-06-05 |
Bret Berner |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
US20030091630A1
(en)
*
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
US20030152622A1
(en)
*
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
WO2003035039A1
(en)
|
2001-10-25 |
2003-05-01 |
Depomed, Inc. |
Methods of treatment using a gastric retained losartan dosage
|
CA2409552A1
(en)
*
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
US20070184104A1
(en)
*
|
2001-10-25 |
2007-08-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
AU2002351798A1
(en)
*
|
2001-10-29 |
2003-05-12 |
Labopharm Inc. |
Methods and dosage forms for improving the bioavailability of therapeutic agents
|
EA200400628A1
(en)
*
|
2001-11-06 |
2004-12-30 |
Рэнбакси Лабораториз Лимитед |
METFORMINE TABLETS WITH CONTROLLED DELIVERY OF THE ACTIVE COMPONENT
|
US6667054B2
(en)
*
|
2001-12-05 |
2003-12-23 |
Bernard Charles Sherman |
Metformin hydrochloride tablets
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
US8128957B1
(en)
|
2002-02-21 |
2012-03-06 |
Valeant International (Barbados) Srl |
Modified release compositions of at least one form of tramadol
|
US8323692B2
(en)
|
2002-02-21 |
2012-12-04 |
Valeant International Bermuda |
Controlled release dosage forms
|
US20050182056A9
(en)
*
|
2002-02-21 |
2005-08-18 |
Seth Pawan |
Modified release formulations of at least one form of tramadol
|
RU2336864C2
(en)
*
|
2002-03-22 |
2008-10-27 |
Цилаг Аг |
Tramadol dosage bands with sustained release
|
KR101061351B1
(en)
|
2002-04-09 |
2011-08-31 |
플라멜 테크놀로지스 |
Oral Suspension of Active Ingredient Microcapsules
|
WO2003099214A2
(en)
*
|
2002-05-23 |
2003-12-04 |
Andrx Corporation |
Biguanide formulations
|
US8911781B2
(en)
|
2002-06-17 |
2014-12-16 |
Inventia Healthcare Private Limited |
Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
GB0214013D0
(en)
*
|
2002-06-18 |
2002-07-31 |
Euro Celtique Sa |
Pharmaceutical product
|
US20050226926A1
(en)
|
2002-07-25 |
2005-10-13 |
Pfizer Inc |
Sustained-release tablet composition of pramipexole
|
PE20040134A1
(en)
*
|
2002-07-25 |
2004-03-06 |
Pharmacia Corp |
PRAMIPEXOL ONCE-A-DAY DOSAGE FORM
|
US7214387B2
(en)
*
|
2002-08-02 |
2007-05-08 |
Penwest Pharmaceuticals Company |
Sustained release formulations of metformin
|
US8216609B2
(en)
*
|
2002-08-05 |
2012-07-10 |
Torrent Pharmaceuticals Limited |
Modified release composition of highly soluble drugs
|
US8268352B2
(en)
*
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
EP1545453B1
(en)
*
|
2002-08-29 |
2009-11-18 |
ActivBiotics Pharma LLC |
Rifalazil for treating infections of clostridium difficile
|
US8084058B2
(en)
|
2002-09-20 |
2011-12-27 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US7959946B2
(en)
|
2002-09-20 |
2011-06-14 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US9060941B2
(en)
|
2002-09-20 |
2015-06-23 |
Actavis, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US7785627B2
(en)
|
2002-09-20 |
2010-08-31 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
AU2003282603A1
(en)
*
|
2002-10-11 |
2004-05-04 |
Depomed Development Ltd |
Gastro-retentive levodopa delivery form
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US20040086566A1
(en)
*
|
2002-11-04 |
2004-05-06 |
Alpharma, Inc. |
Waxy matrix dosage forms
|
US20040131672A1
(en)
*
|
2003-01-07 |
2004-07-08 |
Nilobon Podhipleux |
Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
|
PL378367A1
(en)
|
2003-01-13 |
2006-04-03 |
Dynogen Pharmaceuticals, Inc. |
Method of treating functional bowel disorders
|
EP1603540A2
(en)
*
|
2003-03-14 |
2005-12-14 |
Nirmal Mulye |
A process for preparing sustained release tablets
|
BRPI0408999A
(en)
*
|
2003-04-04 |
2006-03-28 |
Pharmacia Corp |
compressed prolonged oral release multiparticulate tablets
|
US7476403B2
(en)
*
|
2003-06-16 |
2009-01-13 |
Andrx Pharmaceuticals, Llc |
Oral extended-release composition
|
US20050013863A1
(en)
*
|
2003-07-18 |
2005-01-20 |
Depomed, Inc., A Corporation Of The State Of California |
Dual drug dosage forms with improved separation of drugs
|
JP2006528185A
(en)
*
|
2003-07-21 |
2006-12-14 |
アドバンシス ファーマスーティカル コーポレイション |
Antibiotic preparations, their use and preparation
|
EP1648407A4
(en)
*
|
2003-07-21 |
2011-08-31 |
Middlebrook Pharmaceuticals Inc |
Antibiotic product, use and formulation thereof
|
JP2006528189A
(en)
*
|
2003-07-21 |
2006-12-14 |
アドバンシス ファーマスーティカル コーポレイション |
Antibiotic products, their use and formulation
|
DE10361596A1
(en)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Process for producing an anti-abuse dosage form
|
US20070048228A1
(en)
*
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
DE102004032051A1
(en)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Process for the preparation of a secured against misuse, solid dosage form
|
DE102004020220A1
(en)
*
|
2004-04-22 |
2005-11-10 |
Grünenthal GmbH |
Process for the preparation of a secured against misuse, solid dosage form
|
DE102005005446A1
(en)
*
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Break-resistant dosage forms with sustained release
|
DE10336400A1
(en)
*
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Anti-abuse dosage form
|
US8075872B2
(en)
*
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
AP1899A
(en)
*
|
2003-08-08 |
2008-10-10 |
Biovail Lab Int Srl |
Modified-release tablet of bupropion hydrochloride
|
US8758820B2
(en)
*
|
2003-08-11 |
2014-06-24 |
Shionogi Inc. |
Robust pellet
|
EP1653924A4
(en)
*
|
2003-08-12 |
2009-09-09 |
Middlebrook Pharmaceuticals In |
Antibiotic product, use and formulation thereof
|
EP1510208A1
(en)
|
2003-08-22 |
2005-03-02 |
Fournier Laboratories Ireland Limited |
Pharmaceutical composition comprising a combination of metformin and statin
|
AU2004270170B2
(en)
*
|
2003-08-29 |
2011-01-27 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
US8460710B2
(en)
*
|
2003-09-15 |
2013-06-11 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
AU2004289221B2
(en)
*
|
2003-11-04 |
2009-12-17 |
Supernus Pharmaceuticals, Inc |
Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms
|
WO2005062898A2
(en)
*
|
2003-12-24 |
2005-07-14 |
Advancis Pharmaceutical Corporation |
Enhanced absorption of modified release dosage forms
|
EP1750717B1
(en)
*
|
2004-02-11 |
2017-07-19 |
Rubicon Research Private Limited |
Controlled release pharmaceutical compositions with improved bioavailability
|
EP1591114A1
(en)
*
|
2004-03-12 |
2005-11-02 |
Fournier Laboratories Ireland Limited |
Use of metformin and orlistat for the treatment or prevention of obesity
|
KR100772980B1
(en)
|
2004-04-01 |
2007-11-02 |
한미약품 주식회사 |
Controlled release formulation for oral administration of metformin
|
EA011446B1
(en)
|
2004-06-17 |
2009-02-27 |
Форест Лэборэтериз, Инк. |
Preparatory solid oral dosage form of memantine with modified release
|
DE102004032049A1
(en)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Anti-abuse, oral dosage form
|
DE102004032103A1
(en)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Anti-abuse, oral dosage form
|
WO2006014427A1
(en)
*
|
2004-07-02 |
2006-02-09 |
Advancis Pharmaceutical Corporation |
Tablet for pulsed delivery
|
DK1781260T4
(en)
|
2004-08-13 |
2014-06-23 |
Boehringer Ingelheim Int |
Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, process for its preparation and use thereof
|
KR20130003040A
(en)
*
|
2004-08-13 |
2013-01-08 |
베링거 인겔하임 인터내셔날 게엠베하 |
Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
|
EP1802258A4
(en)
|
2004-09-13 |
2015-09-23 |
Chrono Therapeutics Inc |
Biosynchronous transdermal drug delivery
|
KR100760430B1
(en)
*
|
2004-12-31 |
2007-10-04 |
한미약품 주식회사 |
Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof
|
DE102005005449A1
(en)
*
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Process for producing an anti-abuse dosage form
|
CA2606386C
(en)
*
|
2005-04-29 |
2014-06-10 |
Cubist Pharmaceuticals, Inc. |
Therapeutic compositions
|
US20080242642A1
(en)
*
|
2007-04-02 |
2008-10-02 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
US7541347B2
(en)
|
2007-04-02 |
2009-06-02 |
Medicis Pharmaceutical Coropration |
Minocycline oral dosage forms for the treatment of acne
|
US8722650B1
(en)
|
2005-06-24 |
2014-05-13 |
Medicis Pharmaceutical Corporation |
Extended-release minocycline dosage forms
|
US20080241235A1
(en)
*
|
2007-04-02 |
2008-10-02 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
US8252776B2
(en)
|
2007-04-02 |
2012-08-28 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
US7919483B2
(en)
*
|
2005-06-24 |
2011-04-05 |
Medicis Pharmaceutical Corporation |
Method for the treatment of acne
|
US7544373B2
(en)
|
2007-04-02 |
2009-06-09 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
RU2408368C2
(en)
*
|
2005-06-27 |
2011-01-10 |
Биовэйл Лэборэториз Интернэшнл С.Р.Л. |
Modified release bupropion salt preparations
|
JP5490409B2
(en)
|
2005-07-11 |
2014-05-14 |
コルトリア・コーポレーション |
Preparations for the treatment of lipoprotein abnormalities comprising statins and methylnicotinamide derivatives
|
US8778395B2
(en)
*
|
2005-08-11 |
2014-07-15 |
Andrx Labs, Llc |
Diltiazem controlled release formulation and method of manufacture
|
WO2007020508A1
(en)
*
|
2005-08-12 |
2007-02-22 |
Ferring International Center S.A. |
Method and device for dividing granules
|
RU2433821C2
(en)
*
|
2005-08-30 |
2011-11-20 |
Пирамал Лайф Сайнсис Лимитед |
Pharmaceutical composition of metformin with prolonged release and method of its obtaining
|
AU2006308635A1
(en)
|
2005-10-14 |
2007-05-10 |
H. Lundbeck A/S |
Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
US8778924B2
(en)
*
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
US20090176882A1
(en)
|
2008-12-09 |
2009-07-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
CA2641665A1
(en)
*
|
2006-02-10 |
2007-08-16 |
Boehringer Ingelheim International Gmbh |
Modified release formulation
|
WO2007090883A1
(en)
*
|
2006-02-10 |
2007-08-16 |
Boehringer Ingelheim International Gmbh |
Extended release formulation
|
US20070190141A1
(en)
*
|
2006-02-16 |
2007-08-16 |
Aaron Dely |
Extended release opiate composition
|
US20070212414A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Penwest Pharmaceuticals Co. |
Ethanol-resistant sustained release formulations
|
AU2013202441B2
(en)
*
|
2006-04-26 |
2016-02-25 |
Alphapharm Pty Ltd |
Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
|
US20090169617A1
(en)
*
|
2006-04-26 |
2009-07-02 |
Panagiotis Keramidas |
Controlled Release Formulations Comprising Uncoated Discrete Unit(s) and an Extended Release Matrix
|
US8299052B2
(en)
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
SA07280459B1
(en)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
|
CA2674039A1
(en)
*
|
2006-12-28 |
2008-07-17 |
Astellas Pharma Inc. |
Sustained release formulation for tacrolimus
|
JP4592818B2
(en)
|
2007-01-29 |
2010-12-08 |
ハナル バイオファーマ カンパニー リミテッド |
N, N-dimethylimidodicarbonimidic acid diamide acetate, process for producing the same, and pharmaceutical composition containing the same
|
DE102007011485A1
(en)
*
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Dosage form with more difficult abuse
|
US20080064701A1
(en)
*
|
2007-04-24 |
2008-03-13 |
Ramesh Sesha |
Anti-diabetic combinations
|
US20070172525A1
(en)
*
|
2007-03-15 |
2007-07-26 |
Ramesh Sesha |
Anti-diabetic combinations
|
CA2682661C
(en)
|
2007-03-22 |
2017-03-14 |
Dendreon Corporation |
Methods for inducing a natural killer (nk) cell-mediated immune response and for increasing nk cell activity
|
US20080241197A1
(en)
*
|
2007-04-02 |
2008-10-02 |
Medicis Pharmaceutical Corporation |
Minocycline dosage forms for the treatment of acne
|
US20090124650A1
(en)
*
|
2007-06-21 |
2009-05-14 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
|
WO2009004592A1
(en)
*
|
2007-07-03 |
2009-01-08 |
Wockhardt Research Centre |
Vancomycin compositions
|
BRPI0821732A2
(en)
|
2007-12-17 |
2015-06-16 |
Labopharm Inc |
Controlled release formulations, solid dosage form, and use of controlled release formulation
|
RU2493830C2
(en)
*
|
2008-01-25 |
2013-09-27 |
Грюненталь Гмбх |
Drug form
|
US20090246276A1
(en)
*
|
2008-01-28 |
2009-10-01 |
Graham Jackson |
Pharmaceutical Compositions
|
CN101932241A
(en)
*
|
2008-02-05 |
2010-12-29 |
默沙东公司 |
Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
|
CA2716130A1
(en)
*
|
2008-03-04 |
2009-09-11 |
Nazaneen Pourkavoos |
Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
|
CA2720108C
(en)
*
|
2008-03-11 |
2016-06-07 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
US8372432B2
(en)
|
2008-03-11 |
2013-02-12 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
US8551524B2
(en)
*
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
JP5114281B2
(en)
*
|
2008-04-17 |
2013-01-09 |
塩野義製薬株式会社 |
Tablets containing vancomycin hydrochloride
|
AU2009243681B2
(en)
*
|
2008-05-09 |
2013-12-19 |
Grunenthal Gmbh |
Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
|
DK3782611T3
(en)
|
2008-05-15 |
2022-09-05 |
Celgene Corp |
ORAL FORMULATIONS OF CYTIDINE ANALOGUES AND METHODS OF USING THEREOF
|
ZA200903854B
(en)
*
|
2008-06-19 |
2011-02-23 |
Univ Of The Witwatesrand Johannesburg |
A gastroretentive pharmaceutical dosage form
|
US20100003322A1
(en)
*
|
2008-07-03 |
2010-01-07 |
Lai Felix S |
Enteric coated hydrophobic matrix formulation
|
WO2010017310A1
(en)
|
2008-08-06 |
2010-02-11 |
Medicis Pharmaceutical Corporation |
Method for the treatment of acne and certain dosage forms thereof
|
WO2010026467A2
(en)
|
2008-09-04 |
2010-03-11 |
Torrent Pharmaceuticals Ltd. |
Controlled release dosage form of high solubility active ingredient
|
BRPI0913724B8
(en)
|
2008-09-18 |
2021-05-25 |
Purdue Pharma Lp |
extended release dosage forms comprising naltrexone and poly (e-caprolactone) and their preparation
|
CA2738114A1
(en)
*
|
2008-09-22 |
2010-04-08 |
Rubicon Research Private Limited |
Compositions exhibiting delayed transit through the gastrointestinal tract
|
MX2011003749A
(en)
|
2008-10-08 |
2011-09-01 |
Bioplus Life Sciences Pvt Ltd |
Sustained release drug delivery system.
|
AU2009327312A1
(en)
|
2008-12-16 |
2011-08-04 |
Labopharm Europe Limited |
Misuse preventative, controlled release formulation
|
US8828953B2
(en)
|
2009-04-20 |
2014-09-09 |
NaZura BioHealth, Inc. |
Chemosensory receptor ligand-based therapies
|
US9901551B2
(en)
|
2009-04-20 |
2018-02-27 |
Ambra Bioscience Llc |
Chemosensory receptor ligand-based therapies
|
AU2010239311B2
(en)
|
2009-04-20 |
2014-05-22 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
EP2427243A4
(en)
|
2009-05-05 |
2012-11-21 |
Vapogenix Inc |
Novel formulations of volatile anesthetics and methods of use for reducing inflammation
|
PL2456427T3
(en)
|
2009-07-22 |
2015-07-31 |
Gruenenthal Gmbh |
Hot-melt extruded controlled release dosage form
|
EP2997965B1
(en)
|
2009-07-22 |
2019-01-02 |
Grünenthal GmbH |
Tamper-resistant dosage form for oxidation-sensitive opioids
|
US20110052700A1
(en)
*
|
2009-08-31 |
2011-03-03 |
Depomed, Inc. |
Gastric retentive pharmaceutical compositions for immediate and extended release of levosulpiride
|
EP2473195A4
(en)
*
|
2009-08-31 |
2013-01-16 |
Depomed Inc |
Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
|
US20110104273A1
(en)
*
|
2009-11-05 |
2011-05-05 |
Depomed, Inc. |
Gastric retentive pharmaceutical compositions for immediate and extended release of phenylephrine
|
US20110135728A1
(en)
*
|
2009-12-08 |
2011-06-09 |
Miller Jennifer L |
Gastric retentive pharmaceutical compositions for extended release of polypeptides
|
US8597681B2
(en)
|
2009-12-22 |
2013-12-03 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
US9198861B2
(en)
|
2009-12-22 |
2015-12-01 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
ES2606227T3
(en)
*
|
2010-02-03 |
2017-03-23 |
Grünenthal GmbH |
Preparation of a pharmaceutical powder composition by an extruder
|
JP2010120967A
(en)
*
|
2010-02-24 |
2010-06-03 |
Shionogi & Co Ltd |
Tablet containing vancomycin hydrochloride
|
TR201802207T4
(en)
|
2010-03-29 |
2018-03-21 |
Astellas Pharma Inc |
Controlled Release Pharmaceutical Composition.
|
CN104258408B
(en)
*
|
2010-03-31 |
2017-10-03 |
持田制药株式会社 |
Easy taking solid pharmaceutical preparation
|
US8581001B2
(en)
|
2010-04-16 |
2013-11-12 |
Codman & Shurtleff |
Metformin-cysteine prodrug
|
US9289400B2
(en)
|
2010-08-11 |
2016-03-22 |
Drexel University |
D3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
|
MX2013002377A
(en)
|
2010-09-02 |
2013-04-29 |
Gruenenthal Gmbh |
Tamper resistant dosage form comprising inorganic salt.
|
TWI516286B
(en)
|
2010-09-02 |
2016-01-11 |
歌林達股份有限公司 |
Tamper resistant dosage form comprising an anionic polymer
|
EP2621487B1
(en)
|
2010-09-28 |
2017-05-03 |
Depomed, Inc. |
Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
|
EA201370099A1
(en)
|
2010-10-19 |
2013-11-29 |
Элселикс Терапьютикс, Инк. |
THERAPY ON THE BASIS OF LIGANDS OF CHEMOSENSOR RECEPTORS
|
CA2815749C
(en)
|
2010-11-08 |
2019-12-03 |
Albireo Ab |
Ibat inhibitors for the treatment of liver diseases
|
EP2648754A4
(en)
|
2010-12-07 |
2016-02-24 |
Philadelphia Health & Educatio |
Methods of inhibiting metastasis from cancer
|
MX2013007884A
(en)
|
2011-01-07 |
2013-09-13 |
Elcelyx Therapeutics Inc |
Chemosensory receptor ligand-based therapies.
|
AR085689A1
(en)
|
2011-03-07 |
2013-10-23 |
Boehringer Ingelheim Int |
PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR
|
US8476221B2
(en)
|
2011-03-18 |
2013-07-02 |
Halimed Pharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders
|
US8741885B1
(en)
|
2011-05-17 |
2014-06-03 |
Mallinckrodt Llc |
Gastric retentive extended release pharmaceutical compositions
|
US8658631B1
(en)
|
2011-05-17 |
2014-02-25 |
Mallinckrodt Llc |
Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
|
US8858963B1
(en)
|
2011-05-17 |
2014-10-14 |
Mallinckrodt Llc |
Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
|
US9119793B1
(en)
|
2011-06-28 |
2015-09-01 |
Medicis Pharmaceutical Corporation |
Gastroretentive dosage forms for doxycycline
|
US9561241B1
(en)
|
2011-06-28 |
2017-02-07 |
Medicis Pharmaceutical Corporation |
Gastroretentive dosage forms for minocycline
|
LT2736495T
(en)
|
2011-07-29 |
2017-11-10 |
Grünenthal GmbH |
Tamper-resistant tablet providing immediate drug release
|
BR112014001091A2
(en)
|
2011-07-29 |
2017-02-14 |
Gruenenthal Gmbh |
tamper resistant tablet that provides immediate release of the drug
|
CN107049979B
(en)
|
2011-09-30 |
2020-08-14 |
持田制药株式会社 |
Easily administrable solid preparation
|
CA2853949A1
(en)
|
2011-11-01 |
2013-05-10 |
Celgene Corporation |
Methods for treating cancers using oral formulations of cytidine analogs
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
DK2794565T3
(en)
|
2011-12-21 |
2017-11-13 |
Novira Therapeutics Inc |
ANTIVIRAL AGENTS AGAINST HEPATITIS B
|
BR112014019988A8
(en)
|
2012-02-28 |
2017-07-11 |
Gruenenthal Gmbh |
BREAK-RESISTANT DOSAGE FORM COMPRISING A PHARMACOLOGICALLY ACTIVE COMPOUND AND AN ANIONIC POLYMER
|
US9555001B2
(en)
*
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
AR090695A1
(en)
|
2012-04-18 |
2014-12-03 |
Gruenenthal Gmbh |
PHARMACEUTICAL DOSAGE FORM RESISTANT TO ADULTERATION AND RESISTANT TO IMMEDIATE RELEASE OF DOSE
|
WO2013158928A2
(en)
|
2012-04-18 |
2013-10-24 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
EP2874997A4
(en)
|
2012-07-19 |
2016-01-06 |
Univ Drexel |
Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
|
US9555012B2
(en)
|
2012-08-09 |
2017-01-31 |
Dynamis Therapeutics, Inc. |
Methods for maintaining or improving health, well-being and/or a physiological function in a subject
|
US20140150787A1
(en)
*
|
2012-12-04 |
2014-06-05 |
Civitas Therapeutics, Inc. |
Devices and methods for puncturing a capsule to release a powdered medicament therefrom
|
RS61101B1
(en)
|
2013-01-07 |
2020-12-31 |
Univ Pennsylvania |
Compositions and methods for treating cutaneous t cell lymphoma
|
US8652527B1
(en)
|
2013-03-13 |
2014-02-18 |
Upsher-Smith Laboratories, Inc |
Extended-release topiramate capsules
|
US10842802B2
(en)
|
2013-03-15 |
2020-11-24 |
Medicis Pharmaceutical Corporation |
Controlled release pharmaceutical dosage forms
|
US9101545B2
(en)
|
2013-03-15 |
2015-08-11 |
Upsher-Smith Laboratories, Inc. |
Extended-release topiramate capsules
|
WO2014167437A1
(en)
|
2013-03-26 |
2014-10-16 |
Wockhardt Limited |
Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
|
EP2996680A1
(en)
|
2013-03-28 |
2016-03-23 |
Wockhardt Limited |
Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
|
JP6466417B2
(en)
|
2013-05-29 |
2019-02-06 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
A tamper-resistant dosage form with a bimodal release profile
|
CA2907950A1
(en)
|
2013-05-29 |
2014-12-04 |
Grunenthal Gmbh |
Tamper-resistant dosage form containing one or more particles
|
CA2914365C
(en)
|
2013-06-05 |
2022-03-15 |
Synchroneuron, Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
CA2917149C
(en)
|
2013-07-02 |
2021-02-02 |
Cineole Corp., Llc |
Antimicrobial formulation comprising isoamyl hexanoates together with propanoic acid and/or isobutyric acid
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
MX368846B
(en)
|
2013-07-12 |
2019-10-18 |
Gruenenthal Gmbh |
Tamper-resistant dosage form containing ethylene-vinyl acetate polymer.
|
KR101597004B1
(en)
|
2013-07-25 |
2016-02-23 |
씨제이헬스케어 주식회사 |
Pharmaceutical combination comprising sustained-release type metformin and immediate-release type HMG-CoA reductase inhibitor
|
CA2931553C
(en)
|
2013-11-26 |
2022-01-18 |
Grunenthal Gmbh |
Preparation of a powdery pharmaceutical composition by means of cryo-milling
|
US9908915B2
(en)
|
2013-11-26 |
2018-03-06 |
Yale University |
Cell-penetrating compositions and methods using same
|
EP3079692A4
(en)
|
2013-12-09 |
2017-10-18 |
Thomas Jefferson University |
Novel methods of treating a neurodegenerative disease in a mammal in need thereof
|
WO2015157262A1
(en)
|
2014-04-07 |
2015-10-15 |
Women & Infants Hospital Of Rhode Island |
Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
|
CA2947786A1
(en)
|
2014-05-12 |
2015-11-19 |
Grunenthal Gmbh |
Tamper resistant immediate release capsule formulation comprising tapentadol
|
EP3148512A1
(en)
|
2014-05-26 |
2017-04-05 |
Grünenthal GmbH |
Multiparticles safeguarded against ethanolic dose-dumping
|
WO2015195634A1
(en)
|
2014-06-17 |
2015-12-23 |
Celgne Corporation |
Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
|
KR102560954B1
(en)
|
2014-06-25 |
2023-07-31 |
이에이 파마 가부시키가이샤 |
Solid preparation, and method for preventing or reducing discoloration thereof
|
WO2015199146A1
(en)
*
|
2014-06-25 |
2015-12-30 |
味の素株式会社 |
Solid preparation and method for stabilizing same
|
WO2016028753A1
(en)
|
2014-08-20 |
2016-02-25 |
Yale University |
Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
|
LT3182996T
(en)
|
2014-08-22 |
2023-03-10 |
Celgene Corporation |
Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
|
US10213586B2
(en)
|
2015-01-28 |
2019-02-26 |
Chrono Therapeutics Inc. |
Drug delivery methods and systems
|
US10987328B2
(en)
|
2015-02-20 |
2021-04-27 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Controlled release dosage form
|
WO2016132233A1
(en)
|
2015-02-20 |
2016-08-25 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Controlled release oral dosage form of gaba receptor agonist with enhanced pharmacokinetics
|
US10172800B2
(en)
|
2015-02-20 |
2019-01-08 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Controlled release dosage form with enhanced pharmacokinetics
|
US10300032B2
(en)
|
2015-02-20 |
2019-05-28 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Controlled release dosage form
|
EP3285745A1
(en)
|
2015-04-24 |
2018-02-28 |
Grünenthal GmbH |
Tamper-resistant dosage form with immediate release and resistance against solvent extraction
|
WO2016182968A1
(en)
|
2015-05-08 |
2016-11-17 |
Brown University |
Novel syringolin analogues and methods of making and using same
|
BR112017024141A2
(en)
|
2015-05-19 |
2018-07-17 |
Univ Yale |
compositions for treating pathological calcification conditions and methods of using them
|
WO2016201288A1
(en)
|
2015-06-12 |
2016-12-15 |
Brown University |
Novel antibacterial compounds and methods of making and using same
|
NO346258B1
(en)
|
2015-06-30 |
2022-05-16 |
Neurad Ltd |
Novel breathing control modulating compounds, and methods of making and using same
|
JP2018526414A
(en)
|
2015-09-10 |
2018-09-13 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
Protection against oral overdose with abuse-inhibiting immediate release formulations
|
US10905692B2
(en)
|
2015-10-15 |
2021-02-02 |
Agios Pharmaceuticals, Inc. |
Combination therapy for treating malignancies
|
MD3362066T2
(en)
|
2015-10-15 |
2022-08-31 |
Les Laboratoires Servier Sas |
Combination therapy for treating malignancies
|
WO2017066611A1
(en)
|
2015-10-15 |
2017-04-20 |
Celgene Corporation |
Combination therapy for treating malignancies
|
US11135213B2
(en)
|
2015-10-28 |
2021-10-05 |
Yale University |
Quinoline amides and methods of using same
|
US20180371434A1
(en)
|
2015-11-20 |
2018-12-27 |
Yale University |
Compositions for Treating Ectopic Calcification Disorders, and Methods Using Same
|
US10188656B2
(en)
|
2015-12-04 |
2019-01-29 |
Agios Pharmaceuticals, Inc. |
Methods of treatment of malignancies
|
US10441604B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Cholestyramine pellets and methods for preparation thereof
|
US10786529B2
(en)
|
2016-02-09 |
2020-09-29 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
US10441605B2
(en)
|
2016-02-09 |
2019-10-15 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
MA43640A
(en)
|
2016-02-26 |
2018-11-28 |
Agios Pharmaceuticals Inc |
IDH1 INHIBITORS FOR THE TREATMENT OF HEMATOLOGICAL CANCERS AND SOLID TUMORS
|
CA3017797A1
(en)
|
2016-03-17 |
2017-09-21 |
Thiogenesis Therapeutics, Inc. |
Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
US10292977B2
(en)
|
2016-04-11 |
2019-05-21 |
Neurocea, LLC |
Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
|
US10143687B2
(en)
|
2016-04-11 |
2018-12-04 |
Neurocea, LLC |
Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
|
WO2017182861A1
(en)
*
|
2016-04-23 |
2017-10-26 |
Patel Jayendrakumar Dasharathlal |
Tamper resistant pharmaceutical composition
|
US20190119364A1
(en)
|
2016-04-29 |
2019-04-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Compounds and compositions useful for treating metabolic syndrome, and methods using same
|
US20210330599A1
(en)
|
2016-08-01 |
2021-10-28 |
University Of Rochester |
Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
|
US20180042930A1
(en)
|
2016-08-03 |
2018-02-15 |
Celgene Corporation |
Methods of treatment of malignancies
|
CA3032467A1
(en)
|
2016-08-05 |
2018-02-08 |
Yale University |
Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
|
CA3035205A1
(en)
|
2016-09-01 |
2018-03-08 |
Mebias Discovery Llc |
Substituted ureas and methods of making and using same
|
CN116751200A
(en)
|
2016-11-07 |
2023-09-15 |
爱彼特生物制药公司 |
Tricyclic compounds containing substituted pyridones and methods of using the same
|
CA3049529A1
(en)
|
2017-01-06 |
2018-07-12 |
Chrono Therapeutics Inc. |
Transdermal drug delivery devices and methods
|
EP4219486A1
(en)
|
2017-01-19 |
2023-08-02 |
Temple University of the Commonwealth System of Higher Education |
Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use
|
AU2018238138A1
(en)
|
2017-03-21 |
2019-10-17 |
Arbutus Biopharma Corporation |
Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
|
WO2018195084A1
(en)
|
2017-04-17 |
2018-10-25 |
Yale University |
Compounds, compositions and methods of treating or preventing acute lung injury
|
WO2018204787A1
(en)
|
2017-05-05 |
2018-11-08 |
Memorial Sloan Kettering Cancer Center |
Methods of treatment of myeloproliferative neoplasm
|
US10987311B2
(en)
|
2017-06-16 |
2021-04-27 |
Kashiv Specialty Pharmaceuticals, Llc |
Extended release compositions comprising pyridostigmine
|
WO2018232413A1
(en)
|
2017-06-16 |
2018-12-20 |
Kashiv Pharma Llc |
Gastroretentive dosage forms for sustained drug delivery
|
US10588863B2
(en)
|
2017-06-16 |
2020-03-17 |
Kashiv Biosciences, Llc |
Extended release compositions comprising pyridostigmine
|
SG11201912482WA
(en)
|
2017-07-17 |
2020-02-27 |
Lilly Co Eli |
Pharmaceutical compositions
|
WO2019018158A1
(en)
|
2017-07-17 |
2019-01-24 |
Eli Lilly And Company |
Pharmaceutical compositions
|
CA3071345A1
(en)
|
2017-07-28 |
2019-01-31 |
Yale University |
Anticancer drugs and methods of making and using same
|
CN111032019B
(en)
|
2017-08-09 |
2022-07-05 |
阿尔比里奥公司 |
Cholestyramine granules, oral cholestyramine preparation and application thereof
|
EP3679063A4
(en)
|
2017-09-08 |
2021-06-02 |
The Regents of The University of Colorado, A Body Corporate |
Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers
|
CA3076392A1
(en)
|
2017-09-20 |
2019-03-28 |
Thiogenesis Therapeutics, Inc. |
Methods for the treatment of cysteamine sensitive disorders
|
EP3703724A1
(en)
|
2017-11-02 |
2020-09-09 |
NatureCeuticals Sdn. Bhd. |
Extract of orthosiphon stamineus, formulations, and uses thereof
|
WO2019104316A1
(en)
|
2017-11-27 |
2019-05-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compounds, compositions, and methods for treating and/or preventing periodontal disease
|
WO2019126215A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
JP2021506984A
(en)
|
2017-12-18 |
2021-02-22 |
トリス・フアルマ・インコーポレーテツド |
Release-regulated drug powder composition comprising a gastric retention RAFT formation system with trigger pulse drug release
|
WO2019126214A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
|
WO2019125184A1
(en)
|
2017-12-19 |
2019-06-27 |
Auckland Uniservices Limited |
Use of biomarker in cancer therapy
|
AR114309A1
(en)
|
2018-01-24 |
2020-08-19 |
Univ Rockefeller |
ANTIBACTERIAL COMPOUNDS, COMPOSITIONS OF THE SAME, AND METHODS USING THEM
|
WO2019148087A1
(en)
|
2018-01-29 |
2019-08-01 |
Duke University |
Compositions and methods of enhancing 5-hydroxytryptophan bioavailability
|
CA3101966A1
(en)
|
2018-05-29 |
2019-12-05 |
Morningside Venture Investments Limited |
Drug delivery methods and systems
|
CA3101738A1
(en)
|
2018-05-29 |
2019-12-05 |
Cersci Therapeutics, Inc. |
Compounds for pain treatment, compositions comprising same, and methods of using same
|
CN112449637B
(en)
|
2018-06-05 |
2024-03-19 |
阿尔比里奥公司 |
Benzothiazepine compounds and their use as bile acid modulators
|
US10793534B2
(en)
|
2018-06-05 |
2020-10-06 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
CA3061382C
(en)
|
2018-06-18 |
2020-12-15 |
Kashiv Biosciences, Llc |
Extended release compositions comprising pyridostigmine
|
SG11202011891YA
(en)
|
2018-06-19 |
2021-01-28 |
Nat Univ Singapore |
Formulations of 5-hydroxy tryptophan (5-htp) for better bioavailability for various indications
|
US11801226B2
(en)
|
2018-06-20 |
2023-10-31 |
Albireo Ab |
Pharmaceutical formulation of odevixibat
|
BR112020024461A2
(en)
|
2018-06-20 |
2021-03-23 |
Albireo Ab |
pharmaceutical formulation of odevixibat, process for the preparation of the pharmaceutical formulation, and, formulation.
|
US11007142B2
(en)
|
2018-08-09 |
2021-05-18 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
US11549878B2
(en)
|
2018-08-09 |
2023-01-10 |
Albireo Ab |
In vitro method for determining the adsorbing capacity of an insoluble adsorbant
|
US10722457B2
(en)
|
2018-08-09 |
2020-07-28 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
ES2754280A1
(en)
|
2018-10-11 |
2020-04-16 |
Laboratoris Sanifit S L |
Dosage guidelines for IP and IP analogues for the treatment of ectopic calcifications (Machine-translation by Google Translate, not legally binding)
|
US20220017490A1
(en)
|
2018-11-02 |
2022-01-20 |
Celgene Corporation |
Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
|
WO2020092894A1
(en)
|
2018-11-02 |
2020-05-07 |
Celgene Corporation |
Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
|
WO2020092915A1
(en)
*
|
2018-11-02 |
2020-05-07 |
Celgene Corporation |
Solid dispersions for treatment of cancer
|
TWI827760B
(en)
|
2018-12-12 |
2024-01-01 |
加拿大商愛彼特生物製藥公司 |
Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same
|
MX2021008966A
(en)
|
2019-01-30 |
2021-11-04 |
Sanifit Therapeutics S A |
Inositol phosphate compounds for use in increasing tissular perfusion.
|
WO2020159565A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
|
WO2020159588A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
|
US10941127B2
(en)
|
2019-02-06 |
2021-03-09 |
Albireo Ab |
Benzothiadiazepine compounds and their use as bile acid modulators
|
US10975045B2
(en)
|
2019-02-06 |
2021-04-13 |
Aibireo AB |
Benzothiazepine compounds and their use as bile acid modulators
|
KR102186704B1
(en)
*
|
2019-02-18 |
2020-12-04 |
(주)아이엠디팜 |
A sustained-release lipid pre-concentrate and a sustained-release injectable pharmaceutical composition in the form of lipid solution comprising the same
|
US11471508B2
(en)
|
2019-05-09 |
2022-10-18 |
The Feinstein Institutes For Medical Research |
HMGB1 antagonist treatment of diabetic peripheral neuropathy
|
US11555010B2
(en)
|
2019-07-25 |
2023-01-17 |
Brown University |
Diamide antimicrobial agents
|
EP3818983A1
(en)
|
2019-11-11 |
2021-05-12 |
Sanifit Therapeutics S.A. |
Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
|
CA3158276A1
(en)
|
2019-12-04 |
2021-06-10 |
Per-Goran Gillberg |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
FI4069360T3
(en)
|
2019-12-04 |
2024-02-20 |
Albireo Ab |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
JP2023504644A
(en)
|
2019-12-04 |
2023-02-06 |
アルビレオ・アクチボラグ |
Benzothiadiazepine compounds and their use as bile acid modulators
|
US11014898B1
(en)
|
2020-12-04 |
2021-05-25 |
Albireo Ab |
Benzothiazepine compounds and their use as bile acid modulators
|
EP4069361B1
(en)
|
2019-12-04 |
2024-01-03 |
Albireo AB |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
WO2021127456A1
(en)
|
2019-12-19 |
2021-06-24 |
Rain Therapeutics Inc. |
Methods of inhibiting epidermal growth factor receptor proteins
|
WO2021252549A1
(en)
|
2020-06-09 |
2021-12-16 |
Inozyme Pharma, Inc. |
Soluble enpp1 or enpp3 proteins and uses thereof
|
CA3186857A1
(en)
|
2020-08-03 |
2022-02-10 |
Per-Goran Gillberg |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
EP4243831A1
(en)
|
2020-11-12 |
2023-09-20 |
Albireo AB |
Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
|
JP2024500309A
(en)
|
2020-12-04 |
2024-01-09 |
アルビレオ エービー |
Benzothia(di)azepine compounds and their use as bile acid modulators
|
EP4015494A1
(en)
|
2020-12-15 |
2022-06-22 |
Sanifit Therapeutics S.A. |
Processes for the preparation of soluble salts of inositol phosphates
|
EP4036097A1
(en)
|
2021-01-29 |
2022-08-03 |
Sanifit Therapeutics S.A. |
Ip4-4,6 substituted derivative compounds
|
CN116801868A
(en)
|
2021-07-30 |
2023-09-22 |
埃维西亚治疗公司 |
Gastric retention dosage form of 5-hydroxytryptophan
|
WO2023064598A1
(en)
|
2021-10-14 |
2023-04-20 |
Evecxia Therapeutics, Inc. |
A method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
|
WO2024023360A1
(en)
|
2022-07-29 |
2024-02-01 |
Sanifit Therapeutics, S.A. |
Ip5 substituted compounds
|
WO2024023359A1
(en)
|
2022-07-29 |
2024-02-01 |
Sanifit Therapeutics, S.A. |
Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
|
WO2024052895A1
(en)
|
2022-09-06 |
2024-03-14 |
Hadasit Medical Research Services And Development Ltd |
Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders
|